Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Eigild Møller"'
Autor:
Eigild Møller, Søren Anker Pedersen, Pablo Gustavo Vinicoff, Allan Bardow, Joan Lykkeaa, Pia Svendsen, Merete Bakke
Publikováno v:
Toxins, Vol 7, Iss 7, Pp 2481-2493 (2015)
The aim of this prospective open-label study was to treat disabling drooling in children with cerebral palsy (CP) with onabotulinumtoxin A (A/Ona, Botox®) into submandibular and parotid glands and find the lowest effective dosage and least invasive
Externí odkaz:
https://doaj.org/article/9e8faae0615f47fa8940c18191a1fc44
Publikováno v:
Aktuel Nordisk Odontologi. 41:74-85
Publikováno v:
Journal of oral rehabilitation. 46(5)
BACKGROUND Oromandibular dystonia (OMD) with involuntary jaw and tongue movements may be misdiagnosed as temporomandibular disorders (TMD) and because of the complex muscle activity and involvement of several small muscles, OMD is also considered dif
Publikováno v:
Bakke, M, Henriksen, T, Biernat, H B, Dalager, T & Møller, E 2018, ' Interdisciplinary recognizing and managing of drug-induced tardive oromandibular dystonia : two case reports ', Clinical Case Reports, vol. 6, no. 11, pp. 2150-2155 . https://doi.org/10.1002/ccr3.1548
Clinical Case Reports
Clinical Case Reports
Key Clinical MessageTardive dystonia is a risk factor in medical antipsychotic treatment. It oftenbegins with repetitive involuntary jaw and tongue movements resulting inimpaired chewing and detrimental effect on the dentition. The orofacial dysfunct
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f33256b934bfe2bcd9ab3ec117013838
https://curis.ku.dk/ws/files/203077777/Bakke_et_al_2018_Clinical_Case_Reports.pdf
https://curis.ku.dk/ws/files/203077777/Bakke_et_al_2018_Clinical_Case_Reports.pdf
Autor:
Merete Bakke, Allan Bardow, Eigild Møller, Kristian Winge, Joan Lykkeaa, O. Holm, B. Belhage, D. Daugaard
Publikováno v:
Acta Neurologica Scandinavica. 131:51-57
Moller E, Daugaard D, Holm O, Winge K, Bardow A, Lykkeaa J,Belhage B, Bakke M. Repeated treatments of drooling with botulinumtoxin B in neurology.Acta Neurol Scand 2015: 131: 51–57.© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.O
Publikováno v:
University of Copenhagen
Severe drooling is associated with discomfort and psychosocial problems and may constitute a health risk. A variety of different surgical and non-surgical treatments have been used to diminish drooling, some of them with little or uncertain effect an
Publikováno v:
Bakke, M, Dalager, T & Møller, E 2016, What Clinical Strategies Are Applied for Botulinum Toxin Injection in the Oromandibular Region? in R Rosales & D Dressler (eds), Botulinum Toxin Therapy Manual for Dystonia and Spasticity . InTechOpen, Rijeka, pp. 79-95 . https://doi.org/10.5772/64271
Botulinum Toxin Therapy Manual for Dystonia and Spasticity
Botulinum Toxin Therapy Manual for Dystonia and Spasticity
Botulinum neurotoxin (BoNT) inhibits the release of acetylcholine from cholinergic nerve terminals in muscles or salivary glands. With reduced activation, the muscle activity or secretion decreases. Indications for medical, non‐cosmetic use of BoNT
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65eb90e03dfa2d6527ca3bb77ed447da
https://curis.ku.dk/ws/files/173415161/51448.pdf
https://curis.ku.dk/ws/files/173415161/51448.pdf
Oromandibular dystonia involving the lateral pterygoid muscles: Four cases with different complexity
Publikováno v:
Movement Disorders. 22:785-790
The report describes oromandibular dystonia (OMD) in four women with involuntary activity of the lateral pterygoid muscles (LP), causing incapacitating protrusive and lateral jaw movements and displacements, and treatment with botulinum toxin type A
Autor:
Pia Svendsen, Allan Bardow, Joan Lykkeaa, Merete Bakke, Søren Anker Pedersen, Pablo Gustavo Vinicoff, Eigild Møller
Publikováno v:
Toxins
Volume 7
Issue 7
Pages 2481-2493
Toxins, Vol 7, Iss 7, Pp 2481-2493 (2015)
Volume 7
Issue 7
Pages 2481-2493
Toxins, Vol 7, Iss 7, Pp 2481-2493 (2015)
The aim of this prospective open-label study was to treat disabling drooling in children with cerebral palsy (CP) with onabotulinumtoxin A (A/Ona, Botox®) into submandibular and parotid glands and find the lowest effective dosage and least invasive